Grünenthal and Mesoblast partner to develop innovative cell therapy
Category: #health  By Mateen Dalal  Date: 2019-09-11
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Grünenthal and Mesoblast partner to develop innovative cell therapy

Grünenthal will own the exclusive commercialization rights of allogeneic cell therapy candidate MPC-06-ID in Latin America and Europe.

Grünenthal, a pharmaceutical company that offers various therapies like pain management, have inked a partnership deal with Mesoblast Limited, an Australian company renowned for developing allogeneic cellular medicines, to commercialize and develop Phase III allogeneic cell therapy MPC-06-ID that is used to treat chronic low backache caused by degenerative disc disease.

According to reliable sources, Mesoblast will get a milestone payment and upfront amount of US$150 million prior to the product launch, along with future commercialization milestone payments. These transactions involve commitments up to US$45 million within the first year including US$20 million on getting the regulatory approval to initiate a confirmatory Phase III trial in Europe, US$15 million on signing and US$10 million on reaching certain clinical and manufacturing results.

Additionally, cumulative milestone payments could be offered of more than US$1 billion, conditional on the final results of Phase III trials and patient adoption. The company will also be awarded tiered double-digit royalties on drug sales.

Reportedly, Mesoblast is about to conclude a Phase III study for MPC-06-ID in the United States, which would be published in 2020. However, in the earlier U.S. Phase II trial, the company established that a single intra-discal injection of the drug with dosing of six million allogeneic MPCs (mesenchymal precursor cells) resulted in durable and meaningful advancement for patients in functionality and pain intensity for a minimum of three years.

Speaking on the move, Gabriel Baertschi, CEO, Grünenthal, said that this is good for the company as cell-based therapies provide an innovative approach towards pain management. Theoretically, it can deliver long lasting developments in patients beyond symptomatic treatment by restoring or preserving physiological function.

He said that collaborating with Mesoblast to create novel pain therapies for severe low back pain could help execute their strategy to treat patients with high unmet medical needs.

Source Credit: http://investorsmedia.mesoblast.com/static-files/4f0452e2-1103-48bc-b4a1-278504dfdbb6

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook to allow staff to permanently work from home post the pandemic

Facebook to allow staff to permanently work from home post the pandemic

By Mateen Dalal

Social media giant Facebook Inc. is reportedly planning to allow staff to continue working from home even after the Coronavirus pandemic ends. Eligible staff will be able to apply for permanent work from home, although subject to their relevant manag...

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

By Mateen Dalal

Lo! Foods, a Bengaluru-based consumer goods startup has reportedly secured USD 1 million during its pre-series A funding round, which was led by Chona Family Office, the former promoters of the renowned Hamvor Ice Cream. Other investors that partici...

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

By Mateen Dalal

American Airlines and JetBlue had announced their partnership in July last year. According to the Justice Department, the deal may cause inflated fares at major traffic hubs. The United States Department of Justice (DOJ) has reportedly stepped ...